Our previous study was the first to demonstrate that endogenous hyperinsulinemia contributes to cancer development, primarily the earliest events, using mice with reduced dosage of Ins1 in a Ins2-null genetic background [19]. This evidence concerns the gene FOXM1 and Hyperinsulinemia.